ConversationAdam Lange My name is Adam Lange. I'm the Head of Investor Relations. And on behalf of the entire Zealand Pharma team, we are very pleased to see so many of you today. Thanks a lot for spending the next few hours with us. Today, it is exactly -- almost exactly 2 years ago since we did our last Capital Markets event, our obesity R&D event in December 2023, where for the first time, at least towards a broader audience of investors and analysts, we really articulated the ambition of Zealand Pharma ...

Obesity Treatment Landscape - The industry recognizes obesity as a disease influenced by genetics and environmental factors [9][10] - New medications like GLP-1 receptor agonists (semaglutide, tirzepatide) signal the brain to reduce hunger, helping individuals maintain a lower weight set point [12] - Despite the availability of new medications, over 60% of individuals discontinue use within one year, often due to costs exceeding $500 per month and lack of insurance coverage [15] - Disparities in access to obesity care medications exist, with affluent individuals having greater access compared to vulnerable populations [17] - The industry is concerned about counterfeit drugs and unregulated compounding pharmacies offering cheaper versions of obesity care medications [18] - Obesity stigma persists, with individuals often being told to lose weight "the natural way," unlike other chronic diseases [18][19] - The industry believes that the current moment is a "miracle moment" for obesity care, with medications preventing diabetes and heart attacks [20] - New medications are being developed that could provide even more options and benefits to patients [21] Call to Action - The industry needs to fund obesity research to better understand treatment and prevention [21][22] - The industry needs to improve access to obesity care, including lifestyle interventions, medications, and surgery, for all patients [22] - The industry needs to end obesity stigma and treat obesity as a chronic disease [23]